Acurx Pharmaceuticals, Inc. 10-Q

ITEM 5. OTHER INFORMATION None of our directors or officers have adopted , modified , or terminated any trading plans under Rule 10b5-1 of the Exchange Act or any similar arrangements during the three months ended March 31, 2026. ​ ​ 61 Table of Contents ITEM 6. EXHIBITS The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Quarterly Report. Exhibit Number ​ ​ ​ Description of Exhibit 3.1 ​ Certificate of Amendment to the Certificate of Incorporation of Acurx Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on September 22, 2025). 4.1 ​ Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed on April 16, 2026). 4.2 ​ Form of Series H Common Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K filed on April 16, 2026). 10.1 ​ Form of Securities Purchase Agreement, dated as of April 15, 2026 by and among Acurx Pharmaceuticals, Inc. and the purchasers party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on April 16, 2026). 31.1* ​ Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* ​ Certification of Principal Financial and Accounting Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1* ​ Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2* ​ Certification of Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS ​ Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document 101.SCH ​ Inline XBRL Taxonomy Extension Schema Document 101.CAL ​ Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF ​ Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB ​ Inline XBRL Taxonomy Extension Labels Linkbase Document 101.PRE ​ Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 ​ Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit) ​ * These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act, nor shall they be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such filing. ​ ​ ​ 62 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ Acurx Pharmaceuticals, Inc. ​ ​ ​ Date: May 11, 2026 By: /s/ David P. Luci ​ ​ ​ David P. Luci ​ ​ President and Chief Executive Officer ​ ​ (Principal Executive Officer) ​ ​ ​ Date: May 11, 2026 By: /s/ Robert G. Shawah ​ ​ ​ Robert G. Shawah ​ ​ Chief Financial Officer ​ ​ (Principal Financial and Accounting Officer) ​ ​ ​ 63